371P Palbociclib plus endocrine therapy in clinically relevant HR+/HER2- mBC subgroups: A real-world multicenter studyR. Buonaiuto, C. De Angelis, R. Esposito et al.|ESMO Open|2025Cited by 0
36P PROUDER-BC: PROsigna in UnDer-50-year-old patients (pts) with endocrine receptor-positive (ER+) breast cancer (BC) for chemotherapy (CT) prescriptionFrancesco Schettini, G Grazia, Vincenzo Di Lauro et al.|ESMO Open|2025Cited by 0
209P Comparative analysis of clinician and AI decision-making in HR+/HER2- early breast cancer within routine clinical practice and clinical trialR. Buonaiuto, Mario Giuliano, V. Cantile et al.|ESMO Open|2025Cited by 0
347P Chemotherapy (CT) and GnRH analogue (a) benefit in patients (pts)≤50 years (y) with estrogen receptor-positive (ER+)/HER2-negative (-) stage I–II breast cancer (BC) risk-stratified by ProsignaF. Schettini, G Grazia, Vincenzo Di Lauro et al.|Annals of Oncology|2025Cited by 0